AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35854321
Drug: ATLAS 2030
RxNorm normalized name: LACTIC ACID 0.58 g in 100 g TOPICAL LIQUID [Atlas Prep Activator]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATLAS 2030 gait exoskeleton, used for nine sessions bi-weekly of 60 min each.
Trial: 35854324
Drug: Mental distress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mental distress during TB investigation and treatment
Trial: 35854392
Drug: Unified Internet-delivered
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unified Internet-delivered exposure treatment
Trial: 35857405
Drug: Anlotinib (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib (12 mg/day, orally, 2 weeks on and 1 week off, every 3 weeks) plus Toripalimab (240 mg, intravenously over 60 minutes, once every 2 weeks)
Trial: 35857579
Drug: Intradermal delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal delivery of tremelimumab (2 to 20 mg)
Trial: 35858586
Drug: MVA-MERS-S vaccine
RxNorm normalized name: MVA-SARS-2-S
DrugBank: MVA-SARS-2-S (DB16432)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA-MERS-S vaccine (modified vaccinia virus Ankara-based vaccine) administered on days 0 and 28 with a late booster vaccination at 12 ± 4 months.
Trial: 35858849
Drug: Selective Internal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective Internal Radiation Therapy (SIRT) using TheraSpheres
Trial: 35860245
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard therapy with dexamethasone)
Trial: 35860581
Drug: Three-dimensional conformal
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-dimensional conformal radiation therapy (3D-CRT)
Trial: 35861072
Drug: Prehospital administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prehospital administration of thawed plasma (TP)
Trial: 35861296
Drug: Higher-dose rifampicin
RxNorm normalized name: rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher-dose rifampicin (35 mg/kg)
Trial: 35861370
Drug: Acalabrutinib 100
RxNorm normalized name: acalabrutinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acalabrutinib 100 mg twice daily until disease progression or unacceptable toxicity
Trial: 35861706
Drug: Online support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online support group participation (3 times weekly for 6 weeks)
Trial: 35862034
Drug: Elo-KRd (elotuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elo-KRd (elotuzumab and weekly carfilzomib, lenalidomide, and dexamethasone)
Trial: 35862035
Drug: Icotinib (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icotinib (125 mg 3 times daily) until disease progression, death, or treatment discontinuation.
Trial: 35862184
Drug: mHealth app
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mHealth app (BMT4me) designed to promote adherence to immunosuppressant medication and track symptoms
Trial: 35862185
Drug: Remote monitoring
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remote monitoring solutions implementation
Trial: 35862743
Drug: Dihydroartemisinin-piperaquine (DHA-PQP)
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine (DHA-PQP) 2.1/17.1 mg/kg, administered monthly for 3 consecutive months.
Trial: 35863672
Drug: Nab-paclitaxel (level
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nab-paclitaxel (level 2 dose at 75 mg/m²), capecitabine, and radiation therapy after induction chemotherapy
Trial: 35864209
Drug: 150 mm
RxNorm normalized name: Tenscare Electrodes Joint 150 mm Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mm Drug-Coated Balloon (DCB)
Trial: 35865463
Drug: Pharmacogenetic (PGx)
RxNorm normalized name: PGX
DrugBank: Epoprostenol (DB01240)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmacogenetic (PGx) testing prior to chemotherapy initiation
Trial: 35865476
Drug: Early enteral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early enteral nutrition (250 ml/12 h, increased daily to 1000 ml/12 h if tolerated)
Trial: 35865476
Drug: Oral nutrition
RxNorm normalized name: BAGS/TUBES/SUPPLIES FOR ORAL NUTRITION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutrition
Trial: 35867239
Drug: Transcrestal sinus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcrestal sinus floor elevation with injectable xenograft in gel form
Trial: 35867385
Drug: Radioiodine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioiodine treatment (1.1 GBq and 3.7 GBq groups)
Trial: 35867399
Drug: SADL-eM (Spinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SADL-eM (Spinal Cord Injury Activities of Daily Living Education Manual)
Trial: 35867947
Drug: Enzalutamide (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzalutamide (160 mg orally once daily)
Trial: 35867951
Drug: Lenvatinib 20
RxNorm normalized name: LENVATINIB 20MG DAILY DOSE PACK,10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib 20 mg orally once daily plus pembrolizumab 200 mg intravenously once every 3 weeks
Trial: 35868533
Drug: 250 ppm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 ppm inhaled carbon monoxide (CO)
Trial: 35869143
Drug: First therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First therapy
Trial: 35870368
Drug: Modified prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified prophylaxis regimen with alemtuzumab infusion (5 consecutive days for Course 1, 3 consecutive days for Course 2), including intravenous methylprednisolone 500mg and oral prednisone 50mg, along with oral H1 and H2 antihistaminics.
Trial: 35870368
Drug: Standard prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard prophylaxis regimen with alemtuzumab infusion at Bayshore centers.
Trial: 35870702
Drug: JNJ-3989 100
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-3989 100 to 400 mg Q4W
Trial: 35870702
Drug: JNJ-3989 Q4W
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-3989 Q4W (200 mg) plus oral JNJ-6379 250 mg daily for 12 weeks
Trial: 35870926
Drug: Grade 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grade 4 full-year mean daily school-day MVPA
Trial: 35870926
Drug: Students attaining
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Students attaining 30+ minutes of daily school-day MVPA
Trial: 35870979
Drug: Intelligent Physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intelligent Physical Exercise Training (IPET), one hour/week individualized exercise during working hours for 12 weeks, with the first 8 weeks supervised and the last 4 weeks home-administered.
Trial: 35871040
Drug: Intravesical chemotherapy
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical chemotherapy (IVC) with gemcitabine
Trial: 35871040
Drug: Intravesical chemotherapy
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical chemotherapy (IVC) with saline
Trial: 35871310
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (rituximab, BTKi treatment)
Trial: 35871310
Drug: Suboptimal responses
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suboptimal responses post-second dose
Trial: 35871930
Drug: RWR therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RWR therapy (liraglutide, leucine-rich amino acid infusion, hypocaloric diet)
Trial: 35873000
Drug: Tofacitinib (Tofa)
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tofacitinib (Tofa) 5 mg twice a day
Trial: 35873420
Drug: Infant formula
RxNorm normalized name: Infant formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infant formula with 1.5 g/L HMOs (test group 1, TG1)
Trial: 35873420
Drug: Infant formula
RxNorm normalized name: Infant formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infant formula with 2.5 g/L HMOs (test group 2, TG2)
Trial: 35873652
Drug: Salvage radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salvage radiotherapy (SRT) with 70 Gy in 35 fractions, adapted after 50 Gy, with sequential lymph node irradiation for non-responders.
Trial: 35873652
Drug: PSMA-PET imaging
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSMA-PET imaging at baseline and treatment planning consideration for non-responders after 50 Gy.
Trial: 35874156
Drug: Increasing Duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing Duration of rTMS treatment
Trial: 35874156
Drug: Increasing Intensity
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increasing Intensity of rTMS treatment
Trial: 35874156
Drug: Increasing Duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing Duration and Intensity of rTMS treatment
Trial: 35874466
Drug: Neutralizing anti-Tim-3
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutralizing anti-Tim-3 antibodies
Trial: 35874466
Drug: Neutralizing anti-PD-1
RxNorm normalized name: Dianeal PD-2/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutralizing anti-PD-1 antibodies
Trial: 35874564
Drug: Norepinephrine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine at 0.2 μg/kg/min
Trial: 35875816
Drug: Targeted drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted drugs based on druggable ctDNA alterations identified by next-generation sequencing (NGS)
Trial: 35875816
Drug: Physician-chosen treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician-chosen treatment for patients without druggable ctDNA alterations
Trial: 35876660
Drug: Hypoglycemia (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycemia (blood glucose level <3.0 mmol/L)
Trial: 35878676
Drug: Antidepressant drugs
RxNorm normalized name: MAO A Inhibitors, antidepressant drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant drugs (AD) treatment for 6 months
Trial: 35878742
Drug: Total cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total cholesterol >220 mg/dL
Trial: 35880164
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiotherapy (SBRT) regimen delivering 30 Gy in five planned consecutive daily fractions.
Trial: 35880474
Drug: Control (Q1-Q3;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Q1-Q3; NT-proBNP: Q1, ≤1556 pg/mL; Q2, >1556-2816 pg/mL; Q3, >2816-5314 pg/mL)
Trial: 35880941
Drug: Adoptive cell
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adoptive cell therapies
Trial: 35880942
Drug: Adoptive cellular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adoptive cellular therapy (ACT)
Trial: 35881028
Drug: 18 mg
RxNorm normalized name: niacin 18 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 mg lenvatinib + everolimus (5 mg daily)
Trial: 35881028
Drug: 14 mg
RxNorm normalized name: iodine 0.14 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 mg lenvatinib + everolimus (5 mg daily)
Trial: 35882382
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with apparent treatment-resistant hypertension (aTRH)
Trial: 35882447
Drug: CRISPR/Cas9-mediated knockout
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRISPR/Cas9-mediated knockout of TGF-β receptor 2 in OvCa TIL
Trial: 35882728
Drug: PARPi-FL mouthwash
RxNorm normalized name: Paris quadrifolia extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PARPi-FL mouthwash formulation (1,000 nM of PARPi-FL dissolved in 4.5 ml of PEG 300 and 9.5 ml of water)
Trial: 35882728
Drug: New one-step
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: New one-step formulation of PARPi-FL (direct addition of water into a vial containing PARPi-FL and PEG 3350)
Trial: 35887529
Drug: Panel of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panel of biomarkers (Neutrophil gelatinase-associated lipocalin, Kidney injury molecule-1, N-acetyl-beta-D-glucosaminidase, transferrin, ganglioside-activating protein GM2)
Trial: 35887871
Drug: Ozonated water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozonated water irrigator used daily in conjunction with proper home oral hygiene.
Trial: 35887871
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group performing only home oral hygiene.
Trial: 35891921
Drug: Local standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local standard treatment during the 6-month control period
Trial: 35893347
Drug: Sham Scrambler
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham Scrambler Therapy
Trial: 35894077
Drug: Inhibitor of
RxNorm normalized name: Membrane inhibitor of reactive lysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibitor of aldose reductase (zopolrestat)
Trial: 35894609
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of RAASIs and other AHAs
Trial: 35894680
Drug: Referral to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Referral to a specific dental treatment facility
Trial: 35894729
Drug: Oral Ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Ibuprofen 10 mg/kg
Trial: 35894729
Drug: Oral Paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Paracetamol 10 mg/kg
Trial: 35894761
Drug: Dental implant
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental implant treatment (four implants inserted bilaterally in the maxilla)
Trial: 35894761
Drug: Dental implant
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental implant treatment in patients on high-dose antiresorptive medication (HDAR)
Trial: 35895056
Drug: Escitalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (20 mg/d for 12 weeks)
Trial: 35896216
Drug: Benralizumab 30
RxNorm normalized name: benralizumab 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benralizumab 30 mg every 8 weeks during maintenance phase
Trial: 35898141
Drug: Protein-calorie supplement
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein-calorie supplement
Trial: 35898343
Drug: Omicron BA.1+Beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omicron BA.1+Beta (1 or 2 doses)
Trial: 35900079
Drug: Magnetic Seizure
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnetic Seizure Therapy
Trial: 35901693
Drug: LCTOPC1 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCTOPC1 (2 × 106, 1 × 107, or 2 × 107 cells) administered via intraparenchymal injection
Trial: 35902798
Drug: Total neoadjuvant
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total neoadjuvant therapy (radiotherapy: 45 Gy/25 f and concurrent chemotherapy: S-1: 40-60 mg twice a day, followed by six cycles of consolidated chemotherapy (SOX: S-1 and oxaliplatin) and surgery
Trial: 35903448
Drug: n-3 PUFAs
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFAs (2.4 g/day) plus venlafaxine
Trial: 35904708
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of ranibizumab (0.5 mg/0.05 ml) before vitrectomy
Trial: 35904708
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of ranibizumab (0.5 mg/0.05 ml) at the end of vitrectomy
Trial: 35904722
Drug: Lusutrombopag at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lusutrombopag at 3 mg for up to 7 days
Trial: 35904987
Drug: AS01-adjuvanted vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS01-adjuvanted vaccine containing 120 μg of RSVPreF3
Trial: 35904987
Drug: Unadjuvanted vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unadjuvanted vaccine
Trial: 35905198
Drug: Albumin <
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin < 35g/L
Trial: 35905224
Drug: Sevoflurane anesthesia
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane anesthesia with remifentanil followed by propofol administration
Trial: 35906349
Drug: Milvexian 60
RxNorm normalized name: Milvexian
DrugBank: Milvexian (DB16233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milvexian 60 mg single oral dose
Trial: 35906699
Drug: 12-week complementary
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week complementary and alternative medicine (CAM) program delivered by a therapist at a clinic; 20-session program consisting of yoga, Pilates, and dual tasking exercises.
Trial: 35906699
Drug: 12-week complementary
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week complementary and alternative medicine (CAM) program initiated by the participant at home using a tablet and pre-recorded videos; 20-session program consisting of yoga, Pilates, and dual tasking exercises.
Trial: 35906831
Drug: Caspofungin (empiric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin (empiric therapy)
Trial: 35906831
Drug: Preemptive antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive antifungal strategy (arm B)
Trial: 35906881
Drug: Anti-spike neutralizing
RxNorm normalized name: spike lavender oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-spike neutralizing monoclonal antibodies (nMoAbs)
Trial: 35907135
Drug: Talazoparib (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talazoparib (1 mg/day; 0.75 mg/day for moderate renal impairment)
Trial: 35907430
Drug: ChAdOx2 RabG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdOx2 RabG low dose (5×10^10 viral particles), n=3
Trial: 35907430
Drug: ChAdOx2 RabG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdOx2 RabG middle dose (5×10^10 viral particles), n=3
Trial: 35907430
Drug: ChAdOx2 RabG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdOx2 RabG high dose (5×10^10 viral particles), n=6
Trial: 35907430
Drug: Follow-up after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up after 1 year for middle-dose or high-dose recipients
Trial: 35907430
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a licensed rabies vaccine after ChAdOx2 RabG
Trial: 35908658
Drug: Socket suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Socket suspension system
Trial: 35908569
Drug: Baricitinib 4
RxNorm normalized name: baricitinib 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib 4 mg once daily for 10 days
Trial: 35908569
Drug: JAK inhibitors
RxNorm normalized name: Janus-associated kinase (JAK) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JAK inhibitors (including baricitinib) in meta-analysis
Trial: 35908569
Drug: Baricitinib or
RxNorm normalized name: baricitinib Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib or another JAK inhibitor in updated meta-analysis
Trial: 35909254
Drug: Psychiatric medications
RxNorm normalized name: INVESTIGATIONAL DRUGS FOR PSYCHIATRIC DISEASE,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychiatric medications other than benzodiazepines
Trial: 35910354
Drug: 3,4-Methylenedioxymethamphetamine, dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3,4-Methylenedioxymethamphetamine, dosage and duration not available
Trial: 35911528
Drug: Pharmacist-managed warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-managed warfarin therapy (PMWT)
Trial: 35911547
Drug: Multimodal approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal approach combining clinical, imaging, biological and electrocardiographic markers
Trial: 35911547
Drug: Galectin-3 ≧
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galectin-3 ≧ 9 ng/ml
Trial: 35911663
Drug: Atherectomy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atherectomy and DCB (Drug-Coated Balloon)
Trial: 35911702
Drug: Induction immunochemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction immunochemotherapy (iIC) with PD-1 inhibitor plus chemotherapy every 3 weeks for at least two cycles